Dianthus Therapeutics, Inc.
DNTH
Rank in Stocks
#3907
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in... Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Share Price
$75.21
Last synced: 2026-10-19
Market Cap
$4.21B
Change (1 day)
4.33%
Change (1 year)
108.93%
Country
US
Trade Dianthus Therapeutics, Inc. (DNTH)
Category
Healthcare
Revenue for Dianthus Therapeutics, Inc. (DNTH)
Revenue in Jun 2026 TTM: $1.90M
According to Dianthus Therapeutics, Inc. latest financial reports the company's current revenue (TTM) is $1.90M. In 2023 the company made a revenue of $2.83M a decrease compared to the revenue in the year 2022 that was $6.42M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Dianthus Therapeutics, Inc. from 2016 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $1.90M | -69.46% |
| 2024 | $6.24M | 120.63% |
| 2023 | $2.83M | -55.96% |
| 2022 | $6.42M | 334.76% |
| 2021 | $1.48M | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $12.62B | 662,940.97% |
US
|
|
| $2.23B | 116,916.81% |
US
|
|
| $15.74B | 826,807.94% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 316,144.08% |
NL
|
